US-based monitoring solutions provider Edwards Lifesciences has purchased Harpoon Medical for a cash consideration of $100m.

Under the merger agreement, Harpoon is further eligible for up to $150m in pre-specified milestone payments over the coming ten years.

Harpoon Medical focuses on developing beating-heart repair solutions for degenerative mitral regurgitation (DMR).

The firm has designed a system for echo-guided repair of the valve regurgitation through stabilisation of the prolapsed mitral valve leaflet, restoring normal coaptation and valve function.

It is expected that the device could aid therapy during a minimally invasive beating-heart procedure, paving way for early treatment, quick recovery, less morbidity and consistent patient outcomes.

“The investigational system is intended to support Edwards’ structural heart disease treatments and is set to obtain CE-Mark in the near future.”

The investigational system is intended to support Edwards’ structural heart disease treatments and is set to obtain CE-Mark in the near future.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Edwards Lifesciences surgical heart valve therapy corporate vice-president Bernard Zovighian said: “We believe the addition of Harpoon Medical’s technology and talented team will enable even more opportunities to help patients with degenerative mitral regurgitation.

“The unique beating-heart repair procedure for mitral valve patients complements Edwards’ comprehensive portfolio of treatments for structural heart disease, and reinforces our commitment to innovation in cardiac surgery.”

Along with patient-focused solutions for structural heart disease, the firm develops critical care and surgical monitoring devices.

Through partnerships with various clinicians and researchers, the firm works towards addressing unmet healthcare needs with better patient outcomes and quality of life.